Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

19 Dec 2011 11:46

RNS Number : 2354U
Bank of America Merrill Lynch
19 December 2011
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Evolution Group PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Investec PLC and Investec Ltd

(d)

Date dealing undertaken:

16/12/2011

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB0030221864

Purchase

64,932

0.785 GBP

0.755 GBP

Common - ISIN GB0030221864

Sale

56,216

0.785 GBP

0.755 GBP

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB0030221864

Swaps

Long

13,102

0.77 GBP

Common - ISIN GB0030221864

Swaps

Short

15,872

0.77 GBP

Common - ISIN GB0030221864

Swaps

Long

10,536

0.762 GBP

Common - ISIN GB0030221864

Swaps

Short

5,156

0.755 GBP

Common - ISIN GB0030221864

Swaps

Short

2,258

0.772 GBP

Common - ISIN GB0030221864

Swaps

Short

3,763

0.772 GBP

Common - ISIN GB0030221864

Swaps

Short

10,536

0.772 GBP

Common - ISIN GB0030221864

Swaps

Short

2,578

0.777 GBP

Common - ISIN GB0030221864

Swaps

Short

11,558

0.777 GBP

Common - ISIN GB0030221864

Swaps

Short

297

0.763 GBP

Common - ISIN GB0030221864

Swaps

Short

1,835

0.763 GBP

Common - ISIN GB0030221864

Swaps

Short

11,079

0.763 GBP

Common - ISIN GB0030221864

Swaps

Long

20,423

0.773 GBP

Common - ISIN GB0030221864

Swaps

Long

12,155

0.777 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

19/12/2011

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Investec PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Investec PLC and Investec Ltd

(d)

Date dealing undertaken:

16/12/2011

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB00B17BBQ50

Purchase

269,962

3.437 GBP

3.261 GBP

Common - ISIN GB00B17BBQ50

Sale

364,650

3.425 GBP

3.261 GBP

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB00B17BBQ50

Swaps

Short

6,600

3.283 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

101

3.267 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

2,609

3.267 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

1,676

3.408 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

438

3.372 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

1,137

3.375 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

26,435

3.329 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

26,435

3.326 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

41,834

3.326 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

4,043

3.329 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

361

3.417 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

771

3.412 GBP

Common - ISIN GB00B17BBQ50

Swaps

Long

1,036

3.412 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

11,593

3.261 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

7,737

3.301 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

72,500

3.263 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

1,126

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

10,000

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

10,000

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

10,000

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

10,000

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

18,674

3.262 GBP

Common - ISIN GB00B17BBQ50

Swaps

Short

67,100

3.359 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

19/12/2011

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERFKLFFFLFZFBZ
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.